These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 10405831)

  • 1. Human monoclonal antibodies to MN-24 peptide of gp 120 HIV-1.
    Sidorova E
    Hum Antibodies; 1999; 9(2):107-10. PubMed ID: 10405831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human monoclonal antibodies to viral peptides.
    Sidorova E; Borisova T; Lyakisheva L; Rosen A
    Hum Antibodies; 1997; 8(2):65-9. PubMed ID: 9289390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of synthetic peptides for the production of site (amino acid) specific polyclonal and monoclonal antibodies.
    Claassen E; Zegers ND; Laman JD; Boersma WJ
    Year Immunol; 1993; 7():150-61. PubMed ID: 7690507
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1-specific polyclonal and monoclonal antibodies raised with synthetic peptides: characterization and applications.
    Laman JD; Schellekens MM; Paddenburg D; Tersmette M; Langedijk JP; Boersma WJ; Claassen E
    Year Immunol; 1993; 7():63-8. PubMed ID: 7690509
    [No Abstract]   [Full Text] [Related]  

  • 5. Human immunodeficiency virus gp120 glycoprotein detected by a monoclonal antibody to a synthetic peptide.
    Chanh TC; Kennedy RC; Alderete BE; Kanda P; Eichberg JW; Dreesman GR
    Eur J Immunol; 1986 Nov; 16(11):1465-8. PubMed ID: 3023102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural studies of human HIV-1 V3 antibodies.
    Stanfield RL; Wilson IA
    Hum Antibodies; 2005; 14(3-4):73-80. PubMed ID: 16720977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Localization of the HIV-1 gp120 conformational epitope recognized by virus neutralizing monoclonal antibodies 2G12].
    Tumanova OIu; Kuvshinov VN; Il'ichev AA; Nekrasov BG; Ivanisenko VA; Kozlov AP; Sandakhchiev LS
    Mol Biol (Mosk); 2002; 36(4):657-63. PubMed ID: 12173470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
    Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies.
    Sharon M; Görlach M; Levy R; Hayek Y; Anglister J
    Protein Expr Purif; 2002 Apr; 24(3):374-83. PubMed ID: 11922753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural prerequisites for intersubtype B and D antigenicity of the third variable envelope region (V3) of human immunodeficiency virus type 1.
    Lawoko A; Johansson B; Ljunggren J; Fries A; Fredriksson R; Georgievska L; Malmvall B; Pipkorn R; Fenyö EM; Blomberg J
    J Infect Dis; 2000 Jul; 182(1):49-58. PubMed ID: 10882581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
    Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
    Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cloning of human monoclonal Fab fragments against HIV-1 gp120 peptide binding chemokine receptor from phage Fab antibody library].
    Shen H; Mao P; Hong S; Hou J; Yang J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):357-60. PubMed ID: 12665905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial characterization of the apoptosis-inducing receptor for natural human anti-neuroblastoma IgM.
    David K; Heiligtag S; Ollert MW; Teppke M; Vogel CW; Bredehorst R
    Med Pediatr Oncol; 2001 Jan; 36(1):251-7. PubMed ID: 11464898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies decrease the envelope fluidity of HIV-1.
    Harada S; Monde K; Tanaka Y; Kimura T; Maeda Y; Yusa K
    Virology; 2008 Jan; 370(1):142-50. PubMed ID: 17900650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.